In a landmark decision poised to reshape access to one of the world’s most sought-after medications, Health Canada has granted…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
In a landmark decision poised to reshape access to one of the world’s most in-demand medications, Health Canada has granted…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The pharmaceutical landscape for diabetes and weight management medications has undergone a significant shift with Health Canada’s authorization of Dr.…
Read More
Canada’s Drug Agency Data Reveals Evolving Landscape of Drug Approvals and Reimbursement
In April 2026, Canada’s Drug Agency (CDA) unveiled an expanded dataset, offering a comprehensive look at the trends and intricacies…
Read More
Canada Makes History as First G7 Nation to Approve Generic Semaglutide, Sparking Global Debate on Patent Enforcement and Drug Access
In a landmark decision poised to reshape the landscape of diabetes and obesity management, Health Canada has granted authorization to…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide as Novo Nordisk Patent Lapses
In a landmark decision poised to reshape the pharmaceutical landscape and significantly impact patient access and healthcare costs, Health Canada…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The Canadian healthcare landscape is poised for a significant transformation with Health Canada’s authorization of Dr. Reddy’s Laboratories’ generic semaglutide…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide Following Novo Nordisk Patent Lapse, Paving Way for Enhanced Access and Affordability
In a landmark decision poised to significantly reshape the pharmaceutical landscape for diabetes and obesity management, Health Canada has granted…
Read More
Canada Invests C$79 Million in Aspect Biosystems to Accelerate Development of Bioengineered Cellular Medicines for Endocrine and Metabolic Diseases
Vancouver, BC – Aspect Biosystems, a pioneering company in the field of bioengineered cellular medicines, has received a significant C$79…
Read More
